GoKawiilUnapproved retatrutide knockoffs spread through black market ahead of FDA review
Counterfeit versions of retatrutide, an experimental Eli Lilly weight-loss drug not yet submitted for FDA approval, are being sold at spas and on social media despite lacking any regulatory clearance. The drug targets three hormone receptors to suppress appetite and boost calorie burn, with early trial data suggesting significant weight loss, but no legitimate US provider is authorized to prescribe it. ABC Australia reported a case where a counterfeit vial of the drug caused severe liver damage.
GoKawiil's interpretation of the reporting above, not reported fact.
The gap between public demand for next-generation obesity treatments and the slow pace of clinical trials and regulatory approval is fueling a risky underground market. Because these black-market versions are unregulated and unverified, consumers face serious health risks, including organ damage, without any oversight of dosage, purity, or safety.
- Retatrutide won't reach FDA review until 2027, yet unauthorized versions are already circulating widely.
- The drug activates three metabolic pathways, potentially offering stronger weight-loss effects than current GLP-1 drugs.
- A counterfeit vial reportedly caused severe liver injury, highlighting the dangers of unregulated sourcing.
Source: futurism.com — Joe Wilkins, 2026-08-25
Published there as: “Massive Black Market for Unapproved and Potentially Dangerous Obesity Drug Alarms Doctors”
Read the original report → The summary and analysis above are GoKawiil's own, written from reporting by the source above. Facts and quotes belong to the original publisher.